Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective

被引：1

作者：

Elkeraie, Ahmed Fathi ^{[1
]}

Al-Ghamdi, Saeed ^{[2
]}

Abu-Alfa, Ali K. ^{[3
]}

Alotaibi, Torki ^{[4
]}

Alsaedi, Ali Jasim ^{[5
]}

Alsuwaida, Abdulkareem ^{[6
]}

Arici, Mustafa ^{[7
]}

Ecder, Tevfik ^{[1
,8
]}

Ghnaimat, Mohammad ^{[9
]}

Hafez, Mohamed Hany ^{[10
]}

Hassan, Mohamed H. ^{[11
]}

Sqalli, Tarik ^{[12
]}

机构：

[1] Alexandria Univ, Dept Internal Med & Nephrol, Alexandria, Egypt

[2] King Abdulaziz Univ, Coll Med, Dept Med, Jeddah, Saudi Arabia

[3] Amer Univ Beirut, Dept Internal Med, Div Nephrol & Hypertens, Beirut, Lebanon

[4] Sabah Hlth Reg, Hamed Al Essa Organ Transplant Ctr, Transplant Nephrol, Kuwait, Kuwait

[5] Univ Baghdad, Coll Med, Nephrol & Transplantat Ctr, Dept Nephrol, Baghdad, Iraq

[6] King Saud Univ, Dept Med, Riyadh, Saudi Arabia

[7] Hacettepe Univ, Fac Med, Dept Nephrol, Ankara, Turkiye

[8] Istinye Univ, Dept Med, Div Nephrol, Sch Med, Istanbul, Turkiye

[9] Specialty Hosp, Dept Nephrol, Jaber Ibn Hayyan St Shmeisani, Amman, Jordan

[10] Cairo Univ, Dept Nephrol & Med, Cairo, Egypt

[11] Dept Med, Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates

[12] Moroccan Soc Nephrol, Dept Nephrol, Casablanca, Morocco

来源：

INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE | 2024年 / 17卷

关键词：

chronic kidney disease; nephrology referral; screening; sodium-glucose cotransporter-2 inhibitors; CARDIOVASCULAR OUTCOMES; SGLT2; INHIBITORS; PROGRESSION; ALBUMINURIA; HEALTH; RISK; DAPAGLIFLOZIN; HYPERTENSION; ELECTROLYTE; PREVALENCE;

D O I：

10.2147/IJNRD.S430532

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter -2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD.

引用

页码：1 / 16

页数：16

共 50 条

[21] Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, Hiddo J. L.
Kosiborod, Mikhail
Inzucchi, Silvio E.
Cherney, David Z. I.
KIDNEY INTERNATIONAL, 2018, 94 (01) : 26 - 39
[22] Sodium-glucose cotransporter-2 inhibitors: where and when?
Cowie, Martin R.
FUTURE CARDIOLOGY, 2020, 17 (03) : 403 - 406
[23] RE: Gout and sodium-glucose cotransporter-2 inhibitors
Lund, Lars Christian
Hojlund, Mikkel
Henriksen, Daniel Pilsgaard
Hallas, Jesper
Kristensen, Kasper Bruun
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (01) : 114 - 115
[24] Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease A Milestone Achieved
Sarafidis, Pantelis
Papadopoulos, Christodoulos E.
Kamperidis, Vasilios
Giannakoulas, George
Doumas, Michael
HYPERTENSION, 2021, 77 (05) : 1442 - 1455
[25] Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model
Tansawet, Amarit
Looareesuwan, Panu
Teza, Htun
Boongird, Sarinya
Mckay, Gareth J.
Attia, John
Pattanaprateep, Oraluck
Thakkinstian, Ammarin
DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
[26] Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature
Mckenzie, Taylor
Hale, Genevieve M.
Miner, Amelia
Colon, Jean Colon
Evins, Garrett
Wade, Jasmine
HEART FAILURE REVIEWS, 2024, 29 (02) : 549 - 558
[27] Clinical and practical management of sodium-glucose cotransporter type 2 inhibitors in patients with chronic kidney disease
Castillo Moraga, M. J.
Turegano-Yedro, M.
Pallares-Carratala, V
MEDICINA DE FAMILIA-SEMERGEN, 2023, 49
[28] Ameliorative impact of sodium-glucose cotransporter-2 inhibitors in diabetic kidney disease; a mini-review to current evidence
Jahangiri, Dorsa
Najmaldin, Atousa
Bhaskar, Lakkakula V. K. S.
JOURNAL OF RENAL INJURY PREVENTION, 2022, 11 (04):
[29] Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature
Taylor McKenzie
Genevieve M. Hale
Amelia Miner
Jean Colón Colón
Garrett Evins
Jasmine Wade
Heart Failure Reviews, 2024, 29 : 549 - 558
[30] Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases
Berezin, Alexander E.
Berezina, Tetiana A.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2024, 52 (02)

← 1 2 3 4 5 →